Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia
(NASDAQ: RCKT) Delayed: 3.46 +0.11 (3.28%)
Previous Close $3.35    52 Week High $ 
Open $3.38    52 Week Low $ 
Day High $3.50    P/E N/A 
Day Low $3.35    EPS $ 
Volume 2,427,364